Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ENPH -15%, CSTM -12.9%, WGO -9%, VRT -8.2%, MANH -5.2%, CSGP -5.1% (also to acquire Visual Lease), STX -4.5% (also increases dividend), MMYT -4.3%, HLT -4%, SBUX -3.9% (guides SepQ below consensus; global comps fell -7%; suspends FY25 guidance; increases dividend), GEV -3.9%, EDU -3.2%, RHI -3%, EWBC -3%, WSO -3%, ODFL -2.8%, NEP -2.4%, KO -2.2%, ROP -2%, TMO -1.9%, GD -1.9%, DB -1.8%, BKR -1.5%, COOP -1.2%, NEE -1.1%, VMI -1%, BXMT -1%
Other news:
- ANRO -64.8% (Phase 2b study of ALTO-100 did not meet primary endpoint)
- MCD -6.8% (CDC confirms E. coli Outbreak)
- SEDG -5.3% (in sympathy with weak ENPH earnings)
- KYMR -4.4% (announces three scientific presentations at the EORTC-NCI-AACR 2024 Symposium)
- LW -2.9% (in sympathy with E. coli outbreak at MCD)
- HRTG -2.2% (estimates Q3 catastrophe losses)
- RUN -2.1% (in sympathy with weak ENPH earnings)
- PAM -1.9% (Government of the province of Mendoza established 12 month transition period from the expiration date of the hydroelectric use concession of the waters of the Diamante River and other assets of the province's domain)
- TSN -1.6% (in sympathy with E. coli outbreak at MCD)
- OLMA -1.2% (announces results from three preclinical studies that will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics)
- PRQR -1.1% (prices offering of 18.0 mln shares of common stock at $3.50 per share)
- CMA -1% (enters into $100 mln accelerated share repurchase agreement)
Analyst comments:
- CSGP -5.1% (downgraded to Sector Perform from Outperform at RBC Capital Mkts)
- STNG -1.5% (downgraded to Hold from Buy at Stifel)
- ASC -1.4% (downgraded to Hold from Buy at Stifel)
- TFII -1.2% (downgraded to Hold from Buy at Stifel)